Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02692313 · ClinicalTrials.gov registry record · Early Phase 1
Dose Response of Epinephrine
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT02692313 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants.
The verdict
NCT02692313, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.
Interventions
- DRUG Epinephrine
- OTHER Saline infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-06 |
| Est. Completion | 2025-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02692313
The ClinicalTrials.gov registry entry for NCT02692313 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epinephrine is the first listed.
NCT02692313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02692313 about?
NCT02692313 is a clinical study titled "Dose Response of Epinephrine". Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose respon...
What is the current status of trial NCT02692313?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2016-06. Estimated completion is 2025-09.
What interventions are being tested in trial NCT02692313?
The interventions under investigation include: Epinephrine (DRUG), Saline infusion (OTHER).
Who is sponsoring clinical trial NCT02692313?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.